26 C
Vientiane
Monday, June 9, 2025
spot_img
Home Blog Page 930

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities[1].

This transaction delivers a pipeline of drug candidates against validated cancer targets including DLL3[2] and integrin αvβ6[3], as well as a panel of other agents against novel targets in early discovery stage. The Company believes that these next generation drug candidates fit synergistically with Telix’s therapeutics pipeline, enabling expansion to future therapy areas with unmet clinical need.

The technology platform and intellectual property utilizes small, engineered antibody formats that enable highly specific targeting of cancer with radiation, that exhibit fast tumor uptake and blood clearance. This technology has the potential to be highly effective for imaging and treating tumors with a broad range of radioisotopes, with alpha emitters of particular interest. The ImaginAb capabilities combined with Telix’s existing investments in new target development, conjugation and isotope processing has resulted in a platform that has the potential to rapidly create a new portfolio of “next generation” theranostic radiopharmaceuticals.

The transaction adds a state-of-the-art research facility in Los Angeles to Telix’s U.S. operations, complementing the Company’s existing radiochemistry platform at Optimal Tracers (Sacramento, CA), isotope production at ARTMS (Vancouver, Canada) and bioconjugation chemistry at IsoTherapeutics (Angleton, TX). ImaginAb’s team of discovery, protein engineering and radiopharmaceutical development experts will also join the Telix early development team, further enhancing in-house capabilities in antibody engineering, protein characterization and preclinical development.   

Dr. Michael Wheatcroft, Chief Scientist, Telix, said, “The addition of an early-stage pipeline of promising theranostic assets and a novel biologics platform adds new optionality for Telix to create the next generation of precision medicine and therapeutic products, beyond the current clinical-stage pipeline. We are particularly delighted to welcome a talented team of experts, further enhancing Telix’s R&D capabilities.”

Dr. Anna M. Wu, Co-Founder and Board Member, ImaginAb, added, “The innovative radiotherapeutic technology platform is designed to optimize radiopharmaceutical therapies with targeting agents that are more selective and better match the pharmacology and radiobiology of a given radionuclide. The protein engineering and discovery team is excited to join Telix and further unlock the future potential of this platform and theranostic candidates.”

Transaction details

The upfront consideration value was US$45 million (AU$73 million)[4] of which US$10 million (AU$16 million) has been paid to ImaginAb in cash, with US$31 million (AU$50 million) paid in equity through the issue of 2,053,311 fully paid ordinary Telix shares at AU$24.3745 per share[5]. A deferred payment of up to US$4 million will be paid to ImaginAb in equity at the conclusion of a 15-month indemnity period, subject to set-off of any substantiated claims by Telix above a threshold amount. Upfront equity consideration is subject to voluntary escrow (lock-up/leak-out) restrictions[6].

Upon achievement of specific key development and commercial milestones, Telix will pay up to a total of US$185 million (AU$299 million), a portion of which may be paid in cash or equity at Telix’s election[7]. Royalties are also payable on net sales in the low single digits on a limited number of platform and early-stage products after the first four products have been developed, as well as single-digit sublicense fees, as applicable. 

About ImaginAb, Inc.

ImaginAb is a clinical stage global biotechnology company developing the next generation of radiopharmaceutical imaging agent products. These patented products contain engineered antibodies that maintain the specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available positron emission tomography (PET) and optical imaging technology, these novel targeting agents are able to bind specifically to cell surface targets.

Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology.

Jefferies LLC and Stifel, Nicolaus & Company, Incorporated served as financial advisors to ImaginAb on the transaction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Telix’s lead prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[8], by the Australian Therapeutic Goods Administration (TGA)[9], and by Health Canada[10]. Telix has received a positive decision on its Marketing Authorization Application (MAA) for Illuccix submitted in Europe[11].

Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the anticipated benefits of Telix’s transaction with ImaginAb; the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

 ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

[1] Refer to Telix ASX disclosure 13 January 2025.

[2] Delta-like ligand 3, a cell surface protein overexpressed in high-grade neuroendocrine tumors and small cell lung cancer (SCLC).

[3] Integrin αvβ6 is a cell surface protein overexpressed during wound healing and in cancer.

[4] All references to AUD have been converted at the AUD/USD exchange rate of 1.614.  

[5] Volume weighted average price of shares (VWAP) for the 10 trading day period up to and including 10 January 2025. Refer to Appendix 2A lodged with ASX today for further details.

[6] Refer to Appendix 2A lodged with ASX today for further details.

[7] Refer to Appendix 3G lodged with ASX today for further details.

[8] Telix ASX disclosure 20 December 2021.

[9] Telix ASX disclosure 2 November 2021.

[10] Telix ASX disclosure 14 October 2022.

[11] Telix ASX disclosure 17 January 2025.

 

Growth Opportunities in the Generator Service Market, Global, 2024-2034

Digital Advancements Are Driving Transformative Growth Opportunities

SAN ANTONIO, Jan. 31, 2025 /PRNewswire/ — The global generator service market is projected to grow at a rate of 2.8% from 2023 to 2034, driven by rising power demand and increasing customer awareness of digital solutions. Real-time visibility into equipment operations and AI-powered analytics provide critical insights that enhance efficiency, support predictive maintenance, and ensure continuous usage. By leveraging advanced analytics, manufacturers can optimize equipment control, utilization, logistics, and procurement. Among all end-user sectors, predictive applications remain the most essential in the generator market.

Expansion of the Data Center Market Fuels Investment in Digital Services

The rapid expansion of the data center market is a key driver of investment in digital services. As data centers grow, demand for innovative solutions that improve asset performance, enable proactive maintenance, and facilitate real-time management across multiple locations is increasing. Technologies such as Big Data, edge and cloud computing, and AI are shaping sales strategies. Initial adoption is expected to focus on solutions that deliver immediate cost savings and operational benefits, including fuel monitoring, asset tracking, predictive maintenance alerts, and remote monitoring services.

XaaS Models Enhance Competitive Advantage

OEMs are increasingly recognizing the potential of Everything-as-a-Service (XaaS) models. While generator set (genset) rentals have been available for some time and are expected to continue growing, many OEMs are now exploring performance-based contracts. These agreements allow customers to acquire equipment gradually through lease-to-buy options, reducing upfront costs and expanding accessibility.

Lucrecia Gomez, Global Power & Energy Research Director at Frost & Sullivan, comments: “Manufacturing high-quality generators alone will not be enough for long-term success. Over time, diesel gensets will become commodities. Companies that produce gensets must show their capability to provide services that utilize the latest technology and digital service models. Genset OEMs should focus on increasing customer loyalty and exploring new revenue streams through digital services, enhanced sponsorship opportunities, and improved customer awareness..”

She adds, “Deploying value-added tools such as fuel monitoring; asset utilization and tracking; equipment maintenance indications; and remote monitoring will enhance product penetration among targeted end users. These advancements will contribute to faster market growth. We forecast deployment to expand at a 4.7% CAGR to 2034.”

To stay ahead in the rapidly evolving generator service and digital solutions landscape, find out more about the growth opportunities here.

Frost & Sullivan, the growth pipeline company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO and the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth initiatives. Frost & Sullivan leverages over 60 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 40 offices on six continents.

Contact:
Celeste Bailo
Marketing & Communications
Global Customer Experience, Frost & Sullivan
celeste.bailo@frost.com

American Creators Score Major Wins at BIGO Awards Gala 2025

  • American creators like Taylor Breanna, Alexis Elise Scott received major awards at the BIGO Awards Gala in Singapore.
  • With over 1000 guests in attendance, this year’s gala highlights Bigo Live’s top priority of ensuring user safety while fostering freedom and innovation in content creation, offering content creators and viewers a diverse and harmonious experience.

LOS ANGELES, US – Media OutReach Newswire – 30 January 2025 – American creators including Taylor Breanna, Jarran Muse and Alexis Elise Scott, scored major wins at last Friday’s Bigo Live Awards. The highly anticipated BIGO Awards Gala is now in its sixth edition and organized by leading global social live-streaming platform Bigo Live.

This year’s theme, “LIVE YOUR OASIS,” reflects Bigo Live’s dedication to celebrating creativity, community and sustainability while fostering a safe and innovative digital ecosystem. The award ceremony was held at the iconic Marina Bay Sands, Sands Theatre, marking a significant milestone as it returns to Singapore, the birthplace of Bigo Live.

The gala welcomed an audience of over 1,000 in-person attendees from around the world, while more than 140,000 viewers tuned in online. The evening was a dazzling celebration of global connection and creative achievements. Attendees experienced an unforgettable night of recognition, entertainment and interaction, highlighting the platform’s ongoing commitment to fostering an inclusive and innovative environment for creators and audiences worldwide.

Co-hosted by renowned Singaporean actress and radio DJ Vernetta Lopez and stand-up comedian Rishi Budhrani, the evening kicked off with an electrifying opening song lit up by a spirited EDM performance. Thirty-five performers from around the world, including Jarran Muse from America, delivered a spectacular array of acts, ranging from pop, opera, hip-hop and rock music to acrobatics and dance. This dynamic celebration of cultural fusion underscores the universal power of the arts.

The Gala’s centrepiece is the recognition of exceptional content creators. Over 200 creators and families were honored across categories such as “Most Uplifting Livestream,” “Best Family Content,” and “Global Community Builder.” Categories like “Most Popular Host,” “Most Popular Family,” and “Gala Star” highlight the platform’s emphasis on community engagement and inclusivity.

American creators such as Taylor Breanna and Alexis Elise Scott received multiple accolades at the gala, a testament to their popularity. They received trophies and in-app rewards. Because viewers played an active role in the celebration by voting for their favorite creators in real-time during the event, this indicates the popularity of American creators not just in the United States but in other countries.

In 2025, Bigo Live will launch further community initiatives and programs to champion its creators. These include spotlighting the voices of our diverse community, fundraising campaigns for meaningful causes and masterclasses in partnership with non-profit organizations on content creation for education and advocacy.

“We are really glad to see creators like Jarran Muse, Trac Trac and Taylor Breanna have their time in the limelight at the BIGO Awards Gala 2025. Bigo Live is a platform that connects creators of common interests across the world, so it is heartening to see that our creators are connecting with people thousands of miles away, on another continent,” said Eric Kim, Senior Operations Director at Bigo Live.

Commitment to Safety, Innovation and Sustainability in Live Streaming

Digital content consumption continues to grow at an unprecedented pace, positioning livestreaming as a transformative force reshaping the social media landscape. Since its inception in 2016, platforms like Bigo Live have been at the forefront of this evolution, enabling creators to reach global audiences with ease. According to a recent report by Stream Hatchet, Bigo Live ranked as the 7th most popular live-streaming platform worldwide in Q3 2024, reflecting its significant impact on the industry.

Through innovative tools such as a Virtual Live and tailored content incentives, Bigo Live has created a thriving ecosystem for creators and viewers alike. The platform’s continuous investment in technological advancements has empowered users to enhance digital interactions and explore new frontiers in creativity.

Through its User-Generated Content (UGC) policies, including stricter private stream verification, advanced moderation practices to reduce oversight gaps and locally relevant content criteria – Bigo Live strives to make the platform a true online oasis for creators and viewers alike, where creativity thrives and connections flourish.

In alignment with its commitment to a greener future, this year’s gala was a carbon-neutral event. By measuring carbon emissions from materials, transportation and electricity and offsetting them with carbon credits, this initiative marks the first step in identifying emission sources and hotspots. Bigo Live emphasizes its role as a responsible industry leader, setting new standards for environmentally conscious digital platforms.
Hashtag: #bigo #bigolive #bigoawardsgala

The issuer is solely responsible for the content of this announcement.

Bigo Live

Bigo Live is one of the world’s fastest-growing live-streaming social communities where users broadcast in real-time to share life moments, showcase their talents and interact with people from around the world. Bigo Live has around 500 million users in over 150 countries and is currently the market leader in the live streaming industry. Launched in March 2016, Bigo Live is owned by Bigo Technology, based in Singapore.

Extended Reality, the Newest Frontier of the Energy Transition

The need for immersive technologies will reshape business strategies and drive seamless integration across industries

LONDON, Jan. 31, 2025 /PRNewswire/ — The global energy industry is undergoing a transformation driven by decarbonisation and decentralisation, leading to increased digitalisation and the utilisation of extended reality (ER) technologies.

Over the past three years, the foundations of the virtual reality (VR) and augmented/mixed reality (AR-MR) markets have become stronger, with major companies investing billions of dollars to stimulate the growth of these technologies.

Extended reality plays a crucial role in the energy sector’s digital transformation, offering users immersive experiences within intricately designed 3D virtual environments. This integration of immersive technology is changing how industry professionals interact with complex data and processes, ultimately leading to innovative solutions and improved efficiency in energy management and operations.

A Growing Market with Extensive Potential for Partnerships and Collaboration

Frost & Sullivan forecasts an impressive compound annual growth rate (CAGR) of 49.4% in global VR/AR-MR market revenues from 2023 to 2028. This growth is fuelled by continuous advancements in immersive technologies and the increase in both consumer and business interest.

The full potential of industrial extended reality (XR) hardware lies in its adaptability to diverse applications. Unlike consumer solutions, industrial XR often requires customisation for specific sectors, such as energy.

Collaboration across the industry is essential to unlocking this potential. By developing specialised software development kits (SDKs) and advanced functionalities, stakeholders can ensure seamless integration of XR technologies into existing workflows and infrastructure, driving innovation and efficiency across industrial domains.

Seamless Integration of Cross-Industry Solutions

Integrating cross-industry solutions is crucial for successful XR implementations in the power and energy sectors. Leveraging advanced technologies such as AI analytics, digital twins, process simulations, and XR platforms enables companies to simulate asset operations in real time. This approach supports informed decision-making, enhances operational efficiency, and mitigates risks.

For instance, digital twins can facilitate the integration of distributed energy resources (DER) into the grid, enhancing the operation of generation and storage assets, and delivering enhanced customer experiences. By adopting these innovative tools, the power and energy sectors can drive greater resilience, sustainability, and performance.

Lucrecia Gomez, Global Power & Energy Research Director at Frost & Sullivan, comments: “Our annual survey of IT decision-makers revealed that 58% of respondents possess a high or moderate level of expertise in immersive digital services within the energy sector. As the industry matures and the demand for ER continues to rise, the visibility and adoption of these technologies will quickly increase across organisations worldwide.”

Gomez adds: “The majority of organisations (62%) are actively engaged in small, medium, or large-scale trials and proof-of-concept projects involving immersive digital services. Among these technologies, mixed reality (MR) stands out, capturing the highest level of interest, with 20% of respondents expressing that they are very or extremely interested in its applications.”

Looking ahead, augmented reality (AR) and mixed reality (MR) are expected to gain significant traction across various business use cases, including data centres, oil and gas, solar photovoltaics, and nuclear power, among others. These technologies hold immense potential to drive innovation and efficiency in the energy sector.

To stay ahead in the fast-expanding global VR/AR-MR landscape, find out more about the growth opportunities here.

Frost & Sullivan, the growth pipeline company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO and the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth initiatives. Frost & Sullivan leverages over 60 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 40 offices on six continents.

Contact:

Kristina Menzefricke
Marketing & Communications
Global Customer Experience, Frost & Sullivan
kristina.menzefricke@frost.com

DeepSeek Now Available on Clarifai Platform

Clarifai’s Full-Stack AI Platform Enabling Next AI Frontier of Model Inferencing

WASHINGTON, Jan. 31, 2025 /PRNewswire/ — Clarifai, a global leader in AI and pioneer of the full-stack AI platform, today announced that several distilled versions of DeepSeek models are available on the Clarifai platform and users can try them for free for a limited time.

The open source DeepSeek models on the platform are not the one that’s been put to the test against a highly-touted OpenAI model, but they nonetheless mark the beginning of a new frontier in AI that users will no doubt rush to explore.

The DeepSeek models, from the Chinese startup by the same name, focus on “inference-time computing,” a technique that emphasizes multi-step reasoning and iterative refinement during the inference process to generate more accurate and contextually relevant responses. This approach reduces the massive computational costs when compared with other leading AI models, improves efficiency during model training time, and shifts the computational bottleneck from training to inference.

To deploy such models efficiently, companies need tools that scale with their needs so that inference doesn’t become a bottleneck. Clarifai’s Inference Compute Orchestration provides the infrastructure to harness the full potential of this wave of AI.

“The DeepSeek models highlight the importance of optimized model inferencing as the new frontier in AI and underscore the need for tools that can optimize inference at scale,” said Matt Zeiler, Ph.D., Founder and CEO of Clarifai. “Clarifai’s Inference Compute Orchestration addresses this need, offering a unified platform to manage and deploy all AI models efficiently, including open source ones like DeepSeek—on every cloud, on-premise, or on edge devices with the same set of tools.”

In addition, the fact that such powerful DeepSeek models are built with open source software, meaning anyone can use and contribute to them, innovations will move faster than if the models were owned by this or that company, like so many others.

Clarifai’s Compute Orchestration will help organizations navigate the model inferencing era with:

  • Optimized Inference: GPU fractioning packs multiple models on the same GPU, and traffic-based autoscaling rises and drops with traffic, reducing costs without sacrificing performance.
  • Control Center: A unified view for monitoring and managing AI compute resources, models, and deployments across multiple environments. With better insight and control over AI infrastructures, companies can prevent runaway costs.
  • Enterprise-Grade Features: Provide required security and oversight so enterprises can deploy AI in regulated industries.

To start experimenting with DeepSeek models on Clarifai, sign up here.

About Clarifai
Clarifai is a global leader in AI and the pioneer of the full-stack AI platform that helps organizations, teams, and developers build, deploy, and operationalize AI at scale. Clarifai’s cutting-edge AI platform supports today’s modern AI technologies like Large Language Models (LLMs), Large Vision Models (LVMs), Retrieval Augmented Generation (RAG), automated data labeling, high-volume production inference, and more. Founded in 2013, Clarifai is available in cloud, on-premises, or hybrid environments and has been used to build more than 1.5 million AI models with more than 400,000 users in 170 countries. Learn more at www.clarifai.com.

For more information or media requests, contact: pr@clarifai.com.

 

Advanced Sterilization Technology and Picarro Partner to Streamline Process Optimization and EtO Emissions Compliance for Sterilization Facilities

New AST BOAZ EtO Reclamation System integrates with Picarro EtO Monitoring Systems to reduce EtO usage and costs while ensuring regulatory compliance

SANTA CLARA, Calif., Jan. 30, 2025 /PRNewswire/ — Picarro Inc., a global leader in gas monitoring, analytics, and services, has been selected by Advanced Sterilization Technology Inc. (AST), to enable a comprehensive solution that will enable sterilization facilities to recycle and reuse ethylene oxide (EtO) while meeting and exceeding emissions regulations. The AST BOAZ cryogenic abatement and reclamation system captures and converts gaseous EtO back into 100% liquid EtO while Picarro’s systems monitor emissions in and around the sterilization facility. The systems work together to control emissions and maintain regulatory compliance.

“Our patented, award-winning BOAZ system has been operating at four pallet sterilizers in Taiwan for more than two years. It has been shown to recover 90 percent of gaseous EtO, resulting in significant financial savings in capital equipment cost, daily operating cost, and in total EtO emissions control costs,” said Denny Christensen, CEO of AST’s new U.S. sales operations. “By integrating Picarro’s ultra-sensitive EtO monitoring systems with our BOAZ, we can give mutual customers additional confidence in their ability to streamline process optimization and compliance.”

“With the growing pressure to meet increasingly stringent EtO control, abatement, and monitoring requirements under EPA NESHAP and FIFRA, the sterilization industry needs emissions management solutions that deliver trusted data,” said Dave Miller, Vice President of Picarro’s Environmental Solutions Business. “By leveraging Picarro’s leading industrial VOC monitoring technology, AST is helping drive much-needed innovation for process optimization and compliance, giving EtO sterilization providers a powerful and reliable solution to tackle emerging regulatory challenges.”

AST BOAZ System: Capex Savings, Reduced EtO Usage, Lower Utility Costs

The AST BOAZ technology will soon be available worldwide and is ideal for facilities that utilize pure EtO for medical device sterilization. The BOAZ system’s notable benefits are:

  • Significantly reduces capital equipment cost for EtO emission control.
  • Significantly reduces cost of EtO used to sterilize as 90% of the EtO gas from the sterilization process is recovered.
  • Significantly reduces the day-to-day EtO emission control utility operating cost for EtO emission control.
  • Changes the requirements for meeting the EPA requirements as 90% of the EtO emissions are eliminated. This changes the EPA compliance requirements due to a 90% reduction in actual EtO emissions.
  • Environmentally Green, much better for the environment as significantly less EtO is used.

Picarro EtO Solutions: Trusted Data, Expert Guidance, and Comprehensive Support

Effective and profitable sterilization operations demand focus. Picarro’s suite of EtO emissions management services and solutions allows operators to focus on their business while Picarro focuses on compliance. Picarro solutions streamline emissions management for EtO and other hazardous pollutants. The Picarro EtO compliance services and solutions provide:

  • Trusted Data: Workplace Monitoring, Fenceline, and Continuous Emissions Monitoring (CEMS) systems deliver ultra-precise, interference-free detection, analysis, and reporting of EtO.
  • Expert Guidance: Experienced team assesses operations and provides tailored advice for navigating regulatory requirements.
  • World-Class Support: End-to-end services prevent costly downtime, mitigate risks, and avoid compliance penalties.

About Advanced Sterilization Technology

Advanced Sterilization Technology (AST) provides the BOAZ EtO Reclamation system to the EtO sterilization industry. This system returns EtO to the sterilization line and even to its original package after being reclaimed. This not only reduces the use of EtO by as much as 90% it reduces waste in the process.

For more information, visit AST in Booth #559 at MD&M West, February 4-6 in Anaheim, California. Or visit https://www.tast.com.tw/service-EO-recycle.php

About Picarro

Picarro, Inc. is a global leader in advanced gas monitoring and analytics solutions. Coupled with expert services, our offerings deliver trusted data to simplify regulatory compliance, optimize energy infrastructure, and advance scientific research. For more information, visit www.picarro.com.

Contacts:

Denny Christensen
CEO
Advanced Sterilization Technology Inc.
denny@astboaz.com
Mobile: 408-667-6817

Jake Thill
Director of Marketing
Picarro Inc.
jthill@picarro.com

 

Zeus To Launch Next-Gen Film-Cast PTFE Liners Engineered for Flexibility and Superior Strength

Unveiling at MD&M West, the new StreamLiner™ NG catheter liners minimize defects and maximize performance vs. existing film-cast PTFE liners.

ORANGEBURG, S.C., Jan. 30, 2025 /PRNewswire/ — Zeus, a global leader in advanced polymer solutions and catheter manufacturing, announced today its plans to unveil StreamLiner™ NG, the latest addition to the company’s StreamLiner series of ultra-thin-walled catheter liners. The company will unveil this innovation at booth #3001 during next week’s MD&M West trade show in Anaheim, California.

“For years, the Zeus StreamLiner series has set the standard for ultra-thin-walled, high-performance PTFE catheter liners,” noted Suresh Sainath, Chief Technology Officer at Zeus. “Now, we’re adding to this incredible product portfolio by introducing our first film-cast offering to the PTFE StreamLiner family, one that will raise the bar for what engineers can expect in performance from film-cast liners.”

Using a new, proprietary film-cast process, Zeus is able to produce StreamLiner NG with significantly improved consistency when compared to existing film-cast liners, helping to reduce imperfections and pinholes commonly seen in other offerings. This consistency, combined with the exceptional sizing and tolerances of existing StreamLiner™ offerings, results in an ultra-thin liner with remarkable flexibility, mechanical performance, and reliability.

The StreamLiner NG catheter liners are Zeus’ most flexible liners yet—ideal for traversing the most complex vasculatures, such as those found below the knee and above the neck, to deliver critical therapies.

“Given the flexibility film-cast liners provide, engineers prefer them for certain applications but face performance challenges due to surface imperfections and pinholes,” Suresh added. “Our new film-cast liner is the solution. By reducing surface imperfections and pinholes, StreamLiner NG can navigate the most tortuous paths and deliver superior strength and performance, significantly reducing these challenges.”

“Our new StreamLiner NG liners are a testament to our continued drive to help solve market challenges and enable our partners to innovate without compromise,” said Paddy O’Brien, Chief Executive Officer at Zeus. “The past several months have been transformative for our company as we’ve continued to build momentum, push the boundaries of innovation, and redefine what’s possible. I’m energized by the progress we’ve made and look forward to the opportunities that lie ahead as we shape the future of catheter design.”

QUICK FACTS

  • Zeus has developed StreamLiner NG, the latest addition to the StreamLiner series of ultra-thin PTFE catheter liners with max wall thicknesses of 0.001″ (0.025 mm) and below.
  • The proprietary film-cast process used to produce StreamLiner NG helps reduce surface imperfections and pinholes, a common issue with existing film-cast liners.
  • StreamLiner NG liners are the most flexible PTFE catheter liners ever produced by Zeus.
  • Zeus will showcase the new liners in booth #3001 at MD&M West.

RESOURCES

StreamLiner™ NG: Click here to request a prototype run.

ABOUT ZEUS

Zeus, headquartered in Orangeburg, South Carolina, is the world’s leading polymer extrusion and catheter design manufacturer. More than 55 years of experience in medical, aerospace, energy, automotive, fiber optics, and more allows Zeus to achieve its mission to provide solutions, enable innovation, and enhance lives. The company employs over 2,400 people worldwide with facilities in Aiken, Columbia, Gaston, Orangeburg, St. Matthews, South Carolina; Branchburg, New Jersey; Chattanooga, Tennessee; San Jose, California; Arden Hills, Minnesota; Guangzhou, China; and Letterkenny, Ireland. For more information, visit www.zeusinc.com.

 

Eye Level Launches “Summit of Math” – A Personalized Online Math Program for Grades 1-10

FORT LEE BOROUGH, N.J., Jan. 30, 2025 /PRNewswire/ — Eye Level, a global leader in supplemental education, proudly announces the launch of Summit of Math, an innovative online math program designed for students in grades 1-10.

Exploring critical thinking through Summit of Math!
Exploring critical thinking through Summit of Math!

Summit of Math offers a comprehensive, standards-aligned curriculum covering Grades 1-8 Math, Pre-Algebra, Algebra 1, Geometry, and Algebra 2. This state-of-the-art program features Eye Level’s proprietary Walk Me Through technology, delivering real-time guided instruction and continuous assessments. It identifies learning gaps and provides personalized study plans to ensure students master critical math concepts.

Comprehensive Math Curriculum with Real-Time Insights

With an intuitive and user-friendly design, Summit of Math empowers students to start learning immediately. The platform provides instructors with real-time data to pinpoint individual weaknesses and track progress. This data-driven approach helps students seamlessly transition to more advanced topics when ready.

Enhancing Math Skills and Critical Thinking

The launch of Summit of Math complements Eye Level’s existing math programs, equipping students to excel in school and beyond. It is available now at select Eye Level Learning Centers.

For more information or to find a center near you, visit https://www.myeyelevel.com/US/programs/summit_of_math.do or email info.summitofmath@myeyelevel.com.

About Eye Level

Eye Level is a trusted global education provider dedicated to helping each child reach their full potential. With its parent company Daekyo, Eye Level has supported millions of students in over 20 countries, providing personalized learning experiences that inspire academic success and critical thinking.

Contact Information:
Eye Level / Daekyo America
1310 Palisade Ave, Fort Lee, NJ 07024